Severe and inadequately controlled asthma MedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
Conditions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1. 2. Documented history of at least one asthma exacerbation requiring use of systemic corticosteroids (SCS) (oral or IV) ) and any combination thereof for at least 3 consecutive days and an associated physician visit, hospitalization, or emergency room visit due to asthma (within 3 days of the corticosteroid use) in the 12 months prior to V1 (Not applicable to adolescents). 3. 12 to 80 years of age, male and female, BMI and/or = 18 years of age: Increase > and/or = 12% and > and/or = 200 mL. • Participants 12 to and/or = 18 years of age: and/or = 1.5 at V1, 3, 5. 7. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose), with medium to high ICS doses for at least 4 weeks prior to V1. 8. eDiary compliance > and/or = 70% during screening (defined as completed daily eDiary entry and answering "yes" for taking 2 puffs of run-in BFF MDI for any 10 mornings, and any 10 evenings in the last 14 days prior to randomization). 9. No respiratory infection in the 4 weeks prior to randomization, or asthma exacerbation treated with systemic corticosteroid and/or additional ICS treatment in the 4 weeks prior to randomization. 10. Demonstrate acceptable MDI/pMDI administration technique. Are the trial subjects under 18? yes Number of subjects for this age range: 80 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 2394 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 326
Exclusion criteria
Exclusion criteria: 1. Completed treatment for respiratory infection or asthma exacerbation with systemic corticosteroids within 4 weeks of V1. 2a. Participants where, in the opinion of the Investigator, treatment with biological therapy for asthma would be appropriate. 2b. Any marketed or investigational biologics within 3 months or 5 halflives of V1, whichever is longer and must not be used during study duration. 3. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months prior to V1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana). 4. Current evidence of COPD. 5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1. 5b. Use of systemic corticosteroids for any other reason except for the acute treatment of severe asthma exacerbation is prohibited for the duration of the study. 5c. Depot corticosteroid use for any reason within 12 months of V1. 6. Use of LAMA as maintenance treatment, either alone or as part of an inhaled combination therapy, within 12 months prior to V1. 7. Use of oral b2-agonist within 3 months of V1. 8. Use of any immunomodulators or immunosuppressive medication within 3 months or 5 half-lives, whichever is longer, and must not be used during the study duration. 9. Narrow angle glaucoma not adequately treated and/or change in vision that may be relevant, in the opinion of the Investigator, within 3 months of Visit 1. 10. Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s). 11. Hospitalization for asthma within 2 months of Visit 1. 12. Known history of drug or alcohol abuse within 12 months of Visit 1. 13. Regular use of a nebulizer or a home nebulizer for receiving asthma medications. 14. Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does not agree to stop during the study duration. 15. Participation in another clinical study with an Investigational Product. 16. Participants with a known hypersensitivity to beta2-agonists, corticosteroids, anticholinergics, or any component of the MDI or pMDI. 17. Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members. 18. For women only – currently pregnant (confirmed with positive highly sensitive pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable contraception measures, as judged by the Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Main Objective of D5982C00007 1. To assess the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (BGF MDI) relative to Budesonide and Formoterol Fumarate (BFF) MDI and Symbicort Pressurized MDI on lung function in participants with inadequately controlled asthma. Main Objective of Pooled Studies D5982C00007 and D5982C00008 1. To assess the effect of BGF MDI relative to BFF MDI or Symbicort pMDI on asthma exacerbations in participants with inadequately controlled asthma.;Secondary Objective: Secondary Objectives of D5982C00007 1. To assess the effect of BGF MDI relative to BFF MDI or Symbicort pMDI on lung function in participants with inadequately controlled asthma. 2. To assess the effect of BGF MDI relative to BFF MDI or Symbicort pMDI on lung function, PROs, and symptoms in participants with inadequately controlled asthma. Secondary Objectives of Pooled Studies D5982C00007 and D5982C00008 1. To assess the effect of BGF MDI relative to BFF MDI or Symbicort pMDI on asthma exacerbations in participants with inadequately controlled asthma.;Primary end point(s): Primary end point(s) of D5982C00007. 1. Europe (EU): Change from baseline in morning pre-dose trough FEV1 over 24 Weeks. Primary end point(s) of Pooled Studies D5982C00007 and D5982C00008. 1. Rate of severe asthma exacerbations.;Timepoint(s) of evaluation of this end point: D5982C00007. Baseline to week 24. Pooled Studies D5982C00007 and D5982C00008. Treatment period (between week 1 to week 52). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Secondary end point(s) of D5982C00007. 1. Onset of action on Day 1: Absolute change in FEV1 at 5 minutes on Day 1. 2. Change from baseline in FEV1 AUC0-3 over 24 weeks. 3. Percentage of responders in ACQ-7 (=0.5 decrease equals response) over 24 weeks. 4. Percentage of responders in ACQ-5 (=0.5 decrease equals response) over 24 weeks. 5. Percentage of responders in the Asthma Quality of Life Questionnaire for 12 years and older (AQLQ +12) (=0.5 increase equals response) over 24 weeks. 6. Percentage of responders in the St. George’s Respiratory Questionnaire (SGRQ) (=4.0 unit decrease equals response) at Week 24. 7. Rate of severe asthma exacerbations under the Attributable Estimand. Secondary end point(s) of Pooled Studies D5982C00007 and D5982C00008. 1. Time to first severe asthma exacerbation. 2. Rate of moderate/severe asthma exacerbations. 3. Time to first moderate/severe asthma exacerbation.;Timepoint(s) of evaluation of this end point: D5982C00007. Baseline to week 24. Pooled Studies D5982C00007 and D5982C00008. Treatment period (between week 1 to week 52). | — |
Countries
Argentina, Australia, Belgium, Bulgaria, Canada, Chile, Denmark, Hungary, India, Italy, Japan, Korea, Republic of, Netherlands, Peru, Philippines, Poland, Romania, Taiwan, Thailand, United States, Vietnam
Contacts
Public ContactInformation Centre
AstraZeneca AB
Outcome results
None listed